Last reviewed · How we verify
CD30 CAR T-cell — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
CD30 CAR T-cell (CD30 CAR T-cell) — New York Medical College.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CD30 CAR T-cell TARGET | CD30 CAR T-cell | New York Medical College | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CD30 CAR T-cell CI watch — RSS
- CD30 CAR T-cell CI watch — Atom
- CD30 CAR T-cell CI watch — JSON
- CD30 CAR T-cell alone — RSS
Cite this brief
Drug Landscape (2026). CD30 CAR T-cell — Competitive Intelligence Brief. https://druglandscape.com/ci/cd30-car-t-cell. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing